Alirocumab vs Inclisiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Alirocumab · Praluent
Marketed by Regeneron Pharmaceuticals and partners
NCT01507831 · Phase 3 · completed
This randomized, double-blind, placebo-controlled Phase 3 trial (ODYSSEY LONG TERM) gave alirocumab 150 mg or placebo every 2 weeks for 78 weeks, on top of maximum tolerated statins, to 2,341 patients at high cardiovascular risk. Its registered primary objective and primary outcome are long-term safety and tolerability, which have no formal efficacy test, so the registered primary has no met or missed result. The published paper reports the efficacy end point it pre-specified: LDL cholesterol fell 62 percentage points more with alirocumab than with placebo at week 24 (P<0.001). Sources: CT.gov posted results and the peer-reviewed paper (Robinson et al., N Engl J Med 2015). Its registered primary outcome on ClinicalTrials.gov is "Percentage of Participants Who Experienced Adverse Events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: December 2026 · NCT07477704 (registry estimate)
Reported efficacy
DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7) (met)
Result source: NCT03510884
Inclisiran · Leqvio
Marketed by Novartis and partners
NCT03397121 · Phase 3 · completed
The trial randomly assigned 482 participants to double-blind inclisiran or placebo, with 242 receiving inclisiran and 240 receiving placebo. Both primary LDL-C comparisons were statistically significant in favor of inclisiran, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical outcome, supporting a moderate evidence grade.
Next expected readout: November 2026 · NCT06501443 (registry estimate)
Reported efficacy
Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78) (met)
Result source: NCT04652726
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Alirocumab | Inclisiran |
|---|---|---|
| LDL-C, % change | -52.7% vs -0.3%−52.4 vs placeboNCT01926782165 other results
| -49.3% vs 4.2%−53.5 vs placeboNCT0340080076 other results
|
| Non-HDL-C, % change | -51.6% vs 0.7%−52.3 vs placeboNCT0150783187 other results
| -41.2% vs 2.1%−43.3 vs placeboNCT0340080038 other results
|
| ApoB, % change | -52.8% vs 1.2%−54 vs placeboNCT0150783186 other results
| -38.1% vs 0.8%−38.9 vs placeboNCT0340080038 other results
|
| Lp(a), % change | -29.3% vs -3.7%−25.6 vs placeboNCT0150783164 other results
| -9.3% vs 3.6%−12.9 vs placeboNCT0465272634 other results
|
| 3-point MACE (% with event) | —Not posted · NCT04790513 | —Not posted · NCT05004675 |
LDL-C, % change
- Alirocumab
- -52.7% vs -0.3%−52.4 vs placeboNCT01926782
165 other results
- -58.8% vs -0.1% NCT01926782
- -45.7% vs -6.6% NCT01617655
- -48.2% vs -2.3% NCT01644175
- -48.8% vs 9.1% NCT01623115
- -48.7% vs 2.8% NCT01709500
- -48.2% vs 0.8% NCT02585778
- -26.9% vs 8.6% NCT03156621
- -43.8% vs -4.3% NCT02584504
- -70.1% vs -4.3% NCT02584504
- -51.7% vs 4.7% NCT02023879
- -50.2% vs -0.3% NCT01926782
- -51.6% vs -0.1% NCT01926782
- -51.8% vs 0.8% NCT02585778
- -57.1% vs 6.3% NCT02289963
- -62.5% vs 1.6% NCT02107898
- -33.6% vs -4.4% NCT03510884
- -38.2% vs -4.4% NCT03510884
- -50.6% vs -20.7% NCT01644188
- -56% vs -20.3% NCT02715726
- -47.2% vs -15.6% NCT01644474
- -45% vs -14.6% NCT01709513
- -50.6% vs -15.9% NCT01730053
- -36.3% vs -15.9% NCT01730053
- -44.1% vs -5% NCT01730040
- -54% vs -5% NCT01730040
- -55.8% vs 4.4% NCT01663402
- -58.3% vs 4.4% NCT01663402
- -45.7% vs 8% NCT01663402
- -52.8% vs 8.2% NCT01663402
- -23.5% vs 16.4% NCT01663402
- -40.1% vs 14.6% NCT01663402
- -63.3% vs 1.5% NCT01507831
- -64.2% vs 1.4% NCT01507831
- -61% vs 0.8% NCT01507831
- -62.8% vs 0.7% NCT01507831
- -57.8% vs 3.5% NCT01507831
- -56.8% vs 4.4% NCT01507831
- -59.9% vs 4.6% NCT01507831
- -52.4% vs 3.6% NCT01507831
- -58% vs 3.9% NCT01507831
- -58.4% vs 0.3% NCT01926782
- -55.3% vs 1.1% NCT01926782
- -60% vs -0.5% NCT01926782
- -58% vs 1.4% NCT01926782
- -59.4% vs -0.4% NCT01926782
- -62.3% vs -0.3% NCT01926782
- -43.5% vs 5.7% NCT01623115
- -43.8% vs 4.6% NCT01709500
- -44.2% vs 4.6% NCT01709500
- -49.4% vs 2.7% NCT01709500
- -47.1% vs 9% NCT01623115
- -40.3% vs 11.5% NCT01623115
- -46.9% vs -6.6% NCT01617655
- -46.9% vs -6.6% NCT01617655
- -46.3% vs 1.1% NCT01644175
- -47.6% vs 1.7% NCT01644175
- -45.5% vs -6.6% NCT01617655
- -50.7% vs -0.8% NCT01644175
- -43.9% vs 5.7% NCT01623115
- -55.1% vs -0.3% NCT01926782
- -50.3% vs 8.4% NCT01709500
- -43.7% vs 14% NCT01623115
- -42.1% vs -3% NCT01617655
- -42% vs -2.9% NCT01617655
- -42.5% vs 0.5% NCT01644175
- -49.3% vs 8.8% NCT01623115
- -48.1% vs 9.1% NCT01623115
- -53.7% vs 1.6% NCT02326220
- -26.9% vs 8.6% NCT03156621
- -43.4% vs -2.8% NCT02584504
- -70.1% vs -2.8% NCT02584504
- -54.2% vs -3.7% NCT02584504
- -69.9% vs -3.7% NCT02584504
- -54% vs -2.6% NCT02584504
- -69.9% vs -2.6% NCT02584504
- -41.7% vs 3.2% NCT02023879
- -44.8% vs 3.6% NCT02023879
- -42.3% vs 4% NCT02326220
- -54.6% vs 5.1% NCT02023879
- -40.9% vs -0.2% NCT01617655
- -52.3% vs 3.2% NCT02023879
- -55% vs 3.6% NCT02023879
- -51.8% vs 0.3% NCT01926782
- -45.3% vs 1.1% NCT01926782
- -53.9% vs -0.5% NCT01926782
- -47.3% vs 1.4% NCT01926782
- -50.8% vs 3.2% NCT02023879
- -51.5% vs 3.6% NCT02023879
- -48.8% vs 1.4% NCT02585778
- -44.8% vs -0.8% NCT02585778
- -55.3% vs 5.1% NCT02023879
- -50.9% vs 0.7% NCT02585778
- -43.3% vs 2.4% NCT02585778
- -49.4% vs 1.4% NCT02585778
- -64.2% vs -2.7% NCT02107898
- -64.8% vs -2.8% NCT02107898
- -63.7% vs 1.7% NCT02107898
- -46.7% vs -0.8% NCT02585778
- -57.9% vs 4.7% NCT02289963
- -58.4% vs 4.7% NCT02289963
- -53.8% vs 0.7% NCT02585778
- -49.4% vs 2.4% NCT02585778
- -60.2% vs 6% NCT02289963
- -62.5% vs -3.6% NCT02107898
- -64.6% vs -3.4% NCT02107898
- -53.6% vs 3.2% NCT02023879
- -54.1% vs 3.6% NCT02023879
- -54.6% vs -0.4% NCT01926782
- -35.4% vs -3.8% NCT03510884
- -42% vs -3.8% NCT03510884
- -35.4% vs -3.8% NCT03510884
- -42% vs -3.8% NCT03510884
- -34.8% vs 2.3% NCT03510884
- -39.2% vs 2.3% NCT03510884
- -34.8% vs 2.3% NCT03510884
- -39.2% vs 2.3% NCT03510884
- -34.8% vs 2.3% NCT03510884
- -39.2% vs 2.3% NCT03510884
- -34.8% vs 2.3% NCT03510884
- -39.2% vs 2.3% NCT03510884
- -33.6% vs -4.4% NCT03510884
- -38.2% vs -4.4% NCT03510884
- -33.6% vs -4.4% NCT03510884
- -38.2% vs -4.4% NCT03510884
- -33.6% vs -4.4% NCT03510884
- -38.2% vs -4.4% NCT03510884
- -37.9% vs 1.2% NCT01617655
- -51.2% vs -21.8% NCT01644188
- -52.4% vs -22.7% NCT01644188
- -52.4% vs -21.8% NCT01644188
- -49.5% vs -18.3% NCT01644188
- -51.8% vs -19.7% NCT01644188
- -44.2% vs -15.2% NCT01644188
- -48.9% vs -17% NCT01644188
- -57.1% vs -22.2% NCT02715726
- -58.1% vs -22.7% NCT02715726
- -58.7% vs -21.3% NCT02715726
- -48.1% vs -19.6% NCT01644474
- -47% vs -15.6% NCT01709513
- -51.2% vs -18% NCT01709513
- -52.2% vs -17.1% NCT01709513
- -47.3% vs -15.2% NCT01709513
- -49.6% vs -22.1% NCT01730053
- -32.3% vs -22.1% NCT01730053
- -52.6% vs -22.9% NCT01730053
- -35.1% vs -22.9% NCT01730053
- -48.4% vs -8.5% NCT01730040
- -50.5% vs -8.5% NCT01730040
- -53.7% vs -9.2% NCT01730040
- -50.9% vs -9.2% NCT01730040
- -53.5% vs -17% NCT01730053
- -41.5% vs -17% NCT01730053
- -48.6% vs -6.1% NCT01730040
- -57.8% vs -6.1% NCT01730040
- -66.2% vs -51.2% NCT03415178
- -73% vs 2% NCT02938949
- -49.6% vs 0.6% NCT02957682
- -54.2% vs 3% NCT02957682
- -51.4% vs 2.8% NCT02957682
- -50.4% vs 2.4% NCT02957682
- -46.2% vs 4% NCT02957682
- -43.3% vs -0.3% NCT02642159
- -41.7% vs -7% NCT02642159
- -64.5% vs -7.6% NCT02984982
- -63.9% vs -13.4% NCT02984982
- Inclisiran
- -49.3% vs 4.2%−53.5 vs placeboNCT03400800
76 other results
- -56.3% vs 1.3% NCT03399370
- -45.8% vs 3.4% NCT03400800
- -51.3% vs 2.5% NCT03399370
- -45.9% vs 1.6% NCT05888103
- -27.1% vs 1.4% NCT04652726
- -41.1% vs 8.4% NCT03397121
- -38.1% vs 6.2% NCT03397121
- 0.7% vs 2.4% NCT03851705
- -21.6% vs 11.7% NCT04659863
- -45.6% vs 1.4% NCT04873934
- -60% vs -7% NCT04929249
- -23.9% vs -0.1% NCT04652726
- -8.7% vs 3.3% NCT03851705
- -32.5% vs 6.4% NCT04652726
- 1.8% vs -2.9% NCT03851705
- -7.2% vs -1.5% NCT03851705
- -19% vs 2.1% NCT04652726
- -26.0% vs 3.3% NCT04652726
- -27.8% vs 1.5% NCT04652726
- -26.1% vs 1.5% NCT04652726
- -26.1% vs 6.8% NCT04659863
- -24.1% vs 17% NCT04659863
- -17.3% vs 10.2% NCT04659863
- -21.6% vs 11.7% NCT04659863
- -19.3% vs 5.4% NCT04659863
- -44.3% vs 2.4% NCT04873934
- -57.2% vs -2.8% NCT04929249
- -38.4% vs 2.1% NCT02597127
- -52.6% vs 2.1% NCT02597127
- -56.3% vs 9% NCT04666298
- -41.9% vs 2.1% NCT02597127
- -27.9% vs 2.1% NCT02597127
- -44.9% vs 2.1% NCT02597127
- -51.9% vs 9% NCT04666298
- -35.5% vs 2.1% NCT02597127
- -47.6% vs 9% NCT04666298
- -59.5% vs -24.3% NCT05192941
- -47.6% vs 1.7% NCT04666298
- -62.8% vs 1.3% NCT04666298
- -62.4% vs 0.2% NCT04666298
- -50.9% vs -4.3% NCT02597127
- -51.0% vs -4.3% NCT02597127
- -61.5% vs 2.7% NCT04666298
- -65.7% vs 1.2% NCT04666298
- -67.2% vs 2.3% NCT04666298
- -43.3% vs -0.9% NCT02597127
- -54.7% vs -0.9% NCT02597127
- -66.2% vs 4.3% NCT04666298
- -35.4% vs 1.4% NCT02597127
- -50.5% vs 1.4% NCT02597127
- -49.6% vs -4.3% NCT02597127
- -46.4% vs -0.9% NCT02597127
- -39.2% vs 1.4% NCT02597127
- -42.1% vs 1.7% NCT04666298
- -55.5% vs 1.3% NCT04666298
- -55.6% vs 0.2% NCT04666298
- -44.3% vs -4.3% NCT02597127
- -44.3% vs -4.3% NCT02597127
- -53.9% vs 2.7% NCT04666298
- -60.3% vs 1.2% NCT04666298
- -62.0% vs 2.3% NCT04666298
- -36.9% vs -0.9% NCT02597127
- -49.5% vs -0.9% NCT02597127
- -60.5% vs 4.3% NCT04666298
- -29.0% vs 1.4% NCT02597127
- -42.6% vs 1.4% NCT02597127
- -37.1% vs 1.7% NCT04666298
- -52.2% vs 1.3% NCT04666298
- -50.1% vs 0.2% NCT04666298
- -35.7% vs -4.3% NCT02597127
- -46.4% vs 2.7% NCT04666298
- -53% vs 1.2% NCT04666298
- -54.9% vs 2.3% NCT04666298
- -41.4% vs -0.9% NCT02597127
- -55.5% vs 4.3% NCT04666298
- -31.7% vs 1.4% NCT02597127
Non-HDL-C, % change
- Alirocumab
- -51.6% vs 0.7%−52.3 vs placeboNCT01507831
87 other results
- -53.1% vs 0.6% NCT01507831
- -53.7% vs 0.9% NCT01507831
- -43.3% vs -0.3% NCT01926782
- -49.7% vs 0.3% NCT01926782
- -48.9% vs 0.1% NCT01926782
- -52.6% vs 0.2% NCT01926782
- -49.9% vs -0.4% NCT01926782
- -46.5% vs 0.6% NCT01926782
- -42.8% vs 9.6% NCT01623115
- -43.3% vs 9.4% NCT01623115
- -38.4% vs 5.3% NCT01623115
- -41.9% vs -6.2% NCT01617655
- -41.7% vs -6.1% NCT01617655
- -39.1% vs -1.6% NCT01644175
- -40.9% vs -0.5% NCT01644175
- -41.4% vs -6.9% NCT01617655
- -37.4% vs 2.6% NCT01644175
- -42.6% vs 3.1% NCT01709500
- -43.2% vs 3.1% NCT01709500
- -37.9% vs 0.7% NCT02585778
- -44.2% vs 4.8% NCT02023879
- -46.7% vs 5% NCT02023879
- -36.2% vs -4.9% NCT02584504
- -61.1% vs -4.9% NCT02584504
- -35.9% vs -3.5% NCT02584504
- -61.1% vs -3.5% NCT02584504
- -34.9% vs 3% NCT02023879
- -45.3% vs 4.8% NCT02023879
- -46.9% vs 5% NCT02023879
- -45.9% vs 0.7% NCT02585778
- -47.2% vs 4.3% NCT02289963
- -50.1% vs 4.1% NCT02289963
- -54.9% vs 2.6% NCT02107898
- -56% vs 2.6% NCT02107898
- -43.4% vs 3% NCT02023879
- -47.3% vs 3.9% NCT02289963
- -56.3% vs -1.7% NCT02107898
- -35.7% vs 4.7% NCT02326220
- -24.8% vs 8% NCT03156621
- -24.8% vs 8% NCT03156621
- -47.1% vs 2.8% NCT02326220
- -41.6% vs 0.3% NCT01926782
- -37.9% vs 4.1% NCT01709500
- -43.6% vs -0.3% NCT01926782
- -47.2% vs 0.1% NCT01926782
- -44.4% vs 0.2% NCT01926782
- -45.8% vs -0.4% NCT01926782
- -37.4% vs 0.6% NCT01926782
- -31% vs -3.7% NCT03510884
- -35.6% vs -3.7% NCT03510884
- -31% vs -3.7% NCT03510884
- -35.6% vs -3.7% NCT03510884
- -33% vs 2.8% NCT03510884
- -34.7% vs 2.8% NCT03510884
- -33% vs 2.8% NCT03510884
- -34.7% vs 2.8% NCT03510884
- -42.1% vs -19.2% NCT01644188
- -43.7% vs -20.2% NCT01644188
- -42.6% vs -20.6% NCT01644188
- -47% vs -19.4% NCT02715726
- -49.1% vs -20.4% NCT02715726
- -47.4% vs -20.7% NCT02715726
- -40.6% vs -15.1% NCT01644474
- -42.5% vs -16.7% NCT01644474
- -40.2% vs -14.6% NCT01709513
- -46.9% vs -17.1% NCT01709513
- -41.5% vs -15.8% NCT01709513
- -42.7% vs -11.2% NCT01730053
- -31.4% vs -11.2% NCT01730053
- -45.7% vs -14.9% NCT01730053
- -35.6% vs -14.9% NCT01730053
- -36.7% vs -6.3% NCT01730040
- -47.6% vs -6.3% NCT01730040
- -40.5% vs -7.5% NCT01730040
- -50.5% vs -7.5% NCT01730040
- -41.2% vs -18% NCT01730053
- -29.8% vs -18% NCT01730053
- -40.6% vs -7.1% NCT01730040
- -42.3% vs -7.1% NCT01730040
- -37.3% vs -4.7% NCT02642159
- -37% vs 2.5% NCT02957682
- -40.6% vs 1.7% NCT02957682
- -41.1% vs 1.7% NCT02957682
- -44% vs 2.2% NCT02957682
- -40.4% vs 0.7% NCT02957682
- -35.5% vs -9.4% NCT02642159
- -54.5% vs -14.1% NCT02984982
- Inclisiran
- -41.2% vs 2.1%−43.3 vs placeboNCT03400800
38 other results
- -47.4% vs -0.1% NCT03399370
- -34.9% vs 7.4% NCT03397121
- -24% vs 1.2% NCT04652726
- -25.0% vs 1.8% NCT04652726
- -25.7% vs 1.8% NCT04652726
- -6.2% vs -1.1% NCT03851705
- -29% vs 5.1% NCT04652726
- -40.7% vs -0.1% NCT05888103
- 1.3% vs -1.7% NCT03851705
- 0.4% vs 2.5% NCT03851705
- -7.2% vs 2.9% NCT03851705
- -20.1% vs 7.1% NCT04659863
- -23.3% vs 9.4% NCT04659863
- -24% vs 19% NCT04659863
- -54.0% vs 1.3% NCT04666298
- -56.8% vs 2.0% NCT04666298
- -58.7% vs 0.8% NCT04666298
- -57.7% vs 2.0% NCT04666298
- -53.2% vs 1.8% NCT04666298
- -54.1% vs 0.6% NCT04666298
- -54.2% vs 1.0% NCT04666298
- -41.2% vs 1.1% NCT04666298
- -50.1% vs 1.3% NCT04666298
- -52.9% vs 2.0% NCT04666298
- -53.5% vs 0.8% NCT04666298
- -52.0% vs 2.0% NCT04666298
- -47.2% vs 1.8% NCT04666298
- -48.2% vs 0.6% NCT04666298
- -48.0% vs 1.0% NCT04666298
- -35.7% vs 1.1% NCT04666298
- -44.8% vs 1.3% NCT04666298
- -47.9% vs 2.0% NCT04666298
- -48.2% vs 0.8% NCT04666298
- -46.1% vs 2.0% NCT04666298
- -39.8% vs 1.8% NCT04666298
- -43.4% vs 0.6% NCT04666298
- -44.7% vs 1.0% NCT04666298
- -31.4% vs 1.1% NCT04666298
ApoB, % change
- Alirocumab
- -52.8% vs 1.2%−54 vs placeboNCT01507831
86 other results
- -54.3% vs 1.2% NCT01507831
- -55.5% vs 0.5% NCT01507831
- -40.2% vs -0.7% NCT01926782
- -45.1% vs 3.1% NCT01926782
- -44.8% vs -0.3% NCT01926782
- -47.2% vs 3.1% NCT01926782
- -46.4% vs -2.3% NCT01926782
- -41.2% vs 3.6% NCT01926782
- -41.1% vs 4.7% NCT01623115
- -41.4% vs 4.5% NCT01623115
- -34.5% vs 3.1% NCT01623115
- -39% vs -8.7% NCT01617655
- -38.9% vs -8.7% NCT01617655
- -36.7% vs -0.9% NCT01644175
- -37.9% vs -0.4% NCT01644175
- -39.2% vs -9% NCT01617655
- -34.8% vs 3.4% NCT01644175
- -42.8% vs -3.5% NCT01709500
- -43.2% vs -3.5% NCT01709500
- -33.4% vs 3.3% NCT02585778
- -38.9% vs 7.5% NCT02023879
- -40.9% vs 7.7% NCT02023879
- -32.2% vs -6% NCT02584504
- -57.9% vs -6% NCT02584504
- -31.8% vs -4.6% NCT02584504
- -58% vs -4.6% NCT02584504
- -31.3% vs 7% NCT02023879
- -39.7% vs 7.5% NCT02023879
- -41.2% vs 7.7% NCT02023879
- -39.4% vs 3.3% NCT02585778
- -42.3% vs 4.1% NCT02289963
- -45.4% vs 3.8% NCT02289963
- -55% vs -1.6% NCT02107898
- -55.9% vs -2.1% NCT02107898
- -38.4% vs 7% NCT02023879
- -40.9% vs 5.2% NCT02289963
- -54.6% vs -3.3% NCT02107898
- -33.8% vs 1.7% NCT02326220
- -22.5% vs 7.2% NCT03156621
- -22.5% vs 7.2% NCT03156621
- -42.8% vs 1.2% NCT02326220
- -36.7% vs 3.1% NCT01926782
- -35.4% vs -0.9% NCT01709500
- -39% vs -0.7% NCT01926782
- -42% vs -0.3% NCT01926782
- -38.3% vs 3.1% NCT01926782
- -40.8% vs -2.3% NCT01926782
- -33% vs 3.6% NCT01926782
- -27.4% vs -3.6% NCT03510884
- -34.3% vs -3.6% NCT03510884
- -27.4% vs -3.6% NCT03510884
- -34.3% vs -3.6% NCT03510884
- -30% vs 1.1% NCT03510884
- -31.7% vs 1.1% NCT03510884
- -30% vs 1.1% NCT03510884
- -31.7% vs 1.1% NCT03510884
- -40.7% vs -18.3% NCT01644188
- -42.1% vs -19.1% NCT01644188
- -39.7% vs -17.2% NCT01644188
- -43.5% vs -16.2% NCT02715726
- -45.2% vs -17.4% NCT02715726
- -43% vs -16.5% NCT02715726
- -36.7% vs -11% NCT01644474
- -37.3% vs -11.7% NCT01644474
- -36.3% vs -11.2% NCT01709513
- -42.6% vs -14.4% NCT01709513
- -36.1% vs -11.6% NCT01709513
- -36.5% vs -9.8% NCT01730053
- -28.3% vs -9.8% NCT01730053
- -39.5% vs -12.7% NCT01730053
- -30.4% vs -12.7% NCT01730053
- -33.7% vs -4.4% NCT01730040
- -41.9% vs -4.4% NCT01730040
- -37.7% vs -5.1% NCT01730040
- -42.7% vs -5.1% NCT01730040
- -36.1% vs -13.7% NCT01730053
- -29% vs -13.7% NCT01730053
- -38.4% vs -6.9% NCT01730040
- -36.2% vs -6.9% NCT01730040
- -36.4% vs 1.4% NCT02957682
- -39.1% vs 0.2% NCT02957682
- -39% vs 1.1% NCT02957682
- -40.9% vs 2.1% NCT02957682
- -36.7% vs 0.8% NCT02957682
- -33.8% vs -1.6% NCT02642159
- -55.1% vs -16.6% NCT02984982
- Inclisiran
- -38.1% vs 0.8%−38.9 vs placeboNCT03400800
38 other results
- -44.8% vs -1.7% NCT03399370
- -33.1% vs 2.9% NCT03397121
- -19.3% vs 1.7% NCT04652726
- -21.5% vs 4.2% NCT04652726
- -21.9% vs 3.9% NCT04652726
- -5.8% vs 4.5% NCT03851705
- -25.1% vs 2.2% NCT04652726
- -36.6% vs 0.2% NCT05888103
- -0.7% vs 2.8% NCT03851705
- -0.8% vs 3.5% NCT03851705
- -6.4% vs 6.3% NCT03851705
- -14.8% vs 10.6% NCT04659863
- -18.5% vs 4.5% NCT04659863
- -20.3% vs 10% NCT04659863
- -46.8% vs 3.8% NCT04666298
- -50.4% vs 3.9% NCT04666298
- -51.9% vs 2.0% NCT04666298
- -51.9% vs 3.0% NCT04666298
- -46.8% vs 2.8% NCT04666298
- -48.5% vs 1.4% NCT04666298
- -48.8% vs 2.2% NCT04666298
- -37.1% vs 1.1% NCT04666298
- -44.5% vs 3.8% NCT04666298
- -46.7% vs 3.9% NCT04666298
- -48.2% vs 2.0% NCT04666298
- -47.0% vs 3.0% NCT04666298
- -42.0% vs 2.8% NCT04666298
- -44.5% vs 1.4% NCT04666298
- -44.0% vs 2.2% NCT04666298
- -32.5% vs 1.1% NCT04666298
- -38.6% vs 3.8% NCT04666298
- -42.8% vs 3.9% NCT04666298
- -43.4% vs 2.0% NCT04666298
- -40.9% vs 3.0% NCT04666298
- -35.8% vs 2.8% NCT04666298
- -39.9% vs 1.4% NCT04666298
- -39.7% vs 2.2% NCT04666298
- -28.2% vs 1.1% NCT04666298
Lp(a), % change
- Alirocumab
- -29.3% vs -3.7%−25.6 vs placeboNCT01507831
64 other results
- -28.2% vs -3.1% NCT01507831
- -21.3% vs 6.4% NCT01926782
- -19.3% vs 9.8% NCT01926782
- -28.9% vs -5.5% NCT01926782
- -19.6% vs 7% NCT01926782
- -23.5% vs -8.7% NCT01617655
- -20.5% vs -5.9% NCT01644175
- -23.2% vs -1.5% NCT01617655
- -19.7% vs 0% NCT01644175
- -25.2% vs -7.5% NCT01623115
- -15.5% vs 4.1% NCT02023879
- -31.7% vs 1.3% NCT02584504
- -49.6% vs 1.3% NCT02584504
- -5.7% vs 2.2% NCT02023879
- -30.3% vs -10% NCT01709500
- -21.8% vs 4.1% NCT02023879
- -19% vs -0.5% NCT02585778
- -21.2% vs -3.9% NCT01623115
- -24.7% vs -5.6% NCT01709500
- -6.1% vs -1.2% NCT02326220
- -19.6% vs 8.8% NCT03156621
- -19.6% vs 8.8% NCT03156621
- -18.1% vs -4% NCT02326220
- -14% vs 6.4% NCT01926782
- -16.9% vs 9.8% NCT01926782
- -23% vs -0.5% NCT02585778
- -35.9% vs -2.3% NCT02289963
- -39.5% vs 2.5% NCT02107898
- -26.9% vs -5.5% NCT01926782
- -12.4% vs 7% NCT01926782
- -16.5% vs 2.2% NCT02023879
- -33.6% vs -1.7% NCT02289963
- -41.9% vs -0.5% NCT02107898
- -14.7% vs 2.5% NCT03510884
- -22.4% vs 2.5% NCT03510884
- -14.7% vs 2.5% NCT03510884
- -22.4% vs 2.5% NCT03510884
- -12.7% vs -2.5% NCT03510884
- -16% vs -2.5% NCT03510884
- -12.7% vs -2.5% NCT03510884
- -16.0% vs -2.5% NCT03510884
- -27.8% vs -6.1% NCT01644188
- -22.1% vs 1.1% NCT01644188
- -30.3% vs 4.0% NCT02715726
- -30.1% vs 6.3% NCT02715726
- -16.7% vs -12.3% NCT01644474
- -17.2% vs -14.2% NCT01644474
- -25.9% vs -7.3% NCT01709513
- -21.7% vs -4.5% NCT01709513
- -27.9% vs -5.2% NCT01730053
- -22.7% vs -5.2% NCT01730053
- -23.6% vs -20.2% NCT01730040
- -30.8% vs -20.2% NCT01730040
- -20.7% vs 3.5% NCT01730053
- -16% vs 3.5% NCT01730053
- -24% vs -11.7% NCT01730040
- -27.9% vs -11.7% NCT01730040
- -17.7% vs 4.8% NCT02957682
- -25.1% vs -1.7% NCT02957682
- -24.3% vs -1.4% NCT02957682
- -24.7% vs -0.5% NCT02957682
- -22.4% vs -3.3% NCT02957682
- -23.7% vs 3.7% NCT02642159
- -55.8% vs -17.2% NCT02984982
- Inclisiran
- -9.3% vs 3.6%−12.9 vs placeboNCT04652726
34 other results
- -5.0% vs 1.1% NCT04652726
- -7.2% vs 1.1% NCT04652726
- -4.8% vs 4.9% NCT03851705
- -13.4% vs 5.4% NCT04652726
- -23.8% vs 6.4% NCT05888103
- -3.8% vs 15.2% NCT03851705
- -4.6% vs 4.3% NCT03851705
- -1.7% vs -12.1% NCT04659863
- -0.3% vs -16.5% NCT04659863
- -0.7% vs -4.4% NCT04659863
- -35.4% vs 5.5% NCT04666298
- -38.1% vs 4.0% NCT04666298
- -37.2% vs 0.2% NCT04666298
- -37.9% vs -2.4% NCT04666298
- -34.3% vs 4.3% NCT04666298
- -36.2% vs -4.3% NCT04666298
- -31.3% vs 0.9% NCT04666298
- -22.8% vs 3.3% NCT04666298
- -25.5% vs 5.5% NCT04666298
- -21.6% vs 4.0% NCT04666298
- -30.3% vs 0.2% NCT04666298
- -26.0% vs -2.4% NCT04666298
- -24.9% vs 4.3% NCT04666298
- -26.1% vs -4.3% NCT04666298
- -22.8% vs 0.9% NCT04666298
- -16.6% vs 3.3% NCT04666298
- -30.1% vs 5.5% NCT04666298
- -32.2% vs 4.0% NCT04666298
- -31.5% vs 0.2% NCT04666298
- -32.0% vs -2.4% NCT04666298
- -27.1% vs 4.3% NCT04666298
- -30.9% vs -4.3% NCT04666298
- -28.1% vs 0.9% NCT04666298
- -21.8% vs 3.3% NCT04666298
3-point MACE (% with event)
- Alirocumab
- —Not posted · NCT04790513
- Inclisiran
- —Not posted · NCT05004675
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
28 other shared endpoints and safety
Coverage. Alirocumab: 32 of 32 rows · Inclisiran: 32 of 32 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alirocumab Rows use multiple source trials | Inclisiran Rows use multiple source trials |
|---|---|---|
| Apo A1 percent change · % of baseline | 7.5% (n=1058) vs 4.2% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2Wa,b,c,d NCT02957682 · Phase 4 · registry result, not featured evidence | 3% (n=92) vs -1.5% (n=48) placebo @ 51.43wka,b,c,d NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
| Apo A1 percent change · % of baseline No placebo or comparator arm | 3.9% (n=651) @ 168wk75 or 150 mg Q2We,c,f NCT01954394 · Phase 3 · registry result, not featured evidence | 5.5% (n=34) @ 102.86wke,c,f NCT03851705 · Phase 3 · registry result, not featured evidence |
| Apo B percent change · % of baseline No placebo or comparator arm | -43.1% (n=651) @ 168wk75 or 150 mg Q2Wg,e,c,h NCT01954394 · Phase 3 · registry result, not featured evidence | -33.66% (n=277) @ 205.71wkg,e,c,h NCT03060577 · Phase 2 · registry result, not featured evidence |
| Apo B Change mg/dL absolute change · mg/dL | -51 vs -16.8 Standard of Care mg/dL @ 36wka,b,c,i NCT02984982 · Phase 4 · registry result, not featured evidence | -26.1 vs -0.6 placebo mg/dL @ 51.43wka,b,c,i NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
| Apo B Change mg/dL absolute change · mg/dL No placebo or comparator arm | -63.5 mg/dL @ 8wk300 mg Q4Wj,e,c,k NCT02890992 · Phase 2 · registry result, not featured evidence show 7 more doses-5.4 mg/dL @ 8wk150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence -34.2 mg/dL @ 8wk150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence -53.4 mg/dL @ 8wk75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence -15.3 mg/dL @ 8wk75 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence -18.5 mg/dL @ 8wk50 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence -35.3 mg/dL @ 8wk40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence -51.7 mg/dL @ 8wk30 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence | -36.26 mg/dL @ 205.71wke,c,k NCT03060577 · Phase 2 · registry result, not featured evidence |
| Apo-A1 Change mg/dL absolute change · mg/dL | 12 vs 3.8 Standard of Care mg/dL @ 36wka,b,c,i NCT02984982 · Phase 4 · registry result, not featured evidence | 2.7 vs -2.6 placebo mg/dL @ 51.43wka,b,c,i NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
| Apo-A1 Change mg/dL absolute change · mg/dL No placebo or comparator arm | 11 mg/dL @ 8wk300 mg Q4Wj,l,e,c,m NCT02890992 · Phase 2 · registry result, not featured evidence show 7 more doses8 mg/dL @ 8wk150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 7.5 mg/dL @ 8wk150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence -0.4 mg/dL @ 8wk75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 10.5 mg/dL @ 8wk75 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 17.7 mg/dL @ 8wk50 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 11.3 mg/dL @ 8wk40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 4 mg/dL @ 8wk30 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence | 6.9 mg/dL @ 102.86wkl,e,c,m NCT03851705 · Phase 3 · registry result, not featured evidence |
| HDL-C percent change · % of baseline | 10.8% (n=1058) vs 5.5% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2Wa,b,c,d NCT02957682 · Phase 4 · registry result, not featured evidence | 4.4% (n=92) vs 0.9% (n=48) placebo @ 51.43wka,b,c,d NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
| HDL-C percent change · % of baseline No placebo or comparator arm | -0.3% (n=651) @ 168wk75 or 150 mg Q2We,c,f NCT01954394 · Phase 3 · registry result, not featured evidence | 4.1% (n=34) @ 102.86wke,c,f NCT03851705 · Phase 3 · registry result, not featured evidence |
| HDL-C Change mg/dL absolute change · mg/dL | 8.1 vs 4.7 Standard of Care mg/dL @ 36wka,b,c,i NCT02984982 · Phase 4 · registry result, not featured evidence | 1.5 vs -0.1 placebo mg/dL @ 51.43wka,b,c,i NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
| HDL-C Change mg/dL absolute change · mg/dL No placebo or comparator arm | 1.2 mg/dL @ 8wk300 mg Q4Wj,l,e,c,m NCT02890992 · Phase 2 · registry result, not featured evidence show 7 more doses5.9 mg/dL @ 8wk150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 2.2 mg/dL @ 8wk150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 4.9 mg/dL @ 8wk75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 2.4 mg/dL @ 8wk75 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 7.7 mg/dL @ 8wk50 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 5.5 mg/dL @ 8wk40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 5.9 mg/dL @ 8wk30 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence | 0.8 mg/dL @ 102.86wkl,e,c,m NCT03851705 · Phase 3 · registry result, not featured evidence |
| LDL-C absolute change · mg/dL | -63.2 vs -15.5 Standard of Care mg/dL @ 36wka,b,c NCT02984982 · Phase 4 · registry result, not featured evidence | -50.91 vs 0.96 placebo mg/dL @ 72.9wkj,a,b,c NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 1 more dose-48.63 vs 0.31 placebo mg/dL NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
| LDL-C percent change · % of baseline No placebo or comparator arm | -52.2% (n=651) @ 168wk75 or 150 mg Q2Wg,e,c,h NCT01954394 · Phase 3 · registry result, not featured evidence | -46.74% (n=277) @ 205.71wkg,e,c,h NCT03060577 · Phase 2 · registry result, not featured evidence |
| LDL-C absolute change · mg/dL No placebo or comparator arm | -99.4 mg/dL @ 168wk75 or 150 mg Q2Wg,e,c,h NCT01954394 · Phase 3 · registry result, not featured evidence | -60.04 mg/dL @ 205.71wkg,e,c,h NCT03060577 · Phase 2 · registry result, not featured evidence |
| LDL-C percent change · % of baseline Extension (open-label) No placebo or comparator arm | -58.46% (n=14) @ 208wkl,e,c,n NCT01576484 · Phase 2 · registry result, not featured evidence | -45.45% (n=103) @ 47.14wkl,e,c,n NCT05888103 · Phase 3 · registry result, not featured evidence |
| LDL-C 50% Reduction responder rate · % of participants | 21.6% (n=49) vs 0% (n=25) placebo @ 24wkQ2Wj,b,c,o NCT03510884 · Phase 3 show 3 more doses21.6% (n=49) vs 0% (n=25) placebo @ 24wkQ2W NCT03510884 · Phase 3 32.4% (n=52) vs 0% (n=25) placebo @ 24wkQ4W NCT03510884 · Phase 3 32.4% (n=52) vs 0% (n=25) placebo @ 24wkQ4W NCT03510884 · Phase 3 | 45.3% (n=201) vs 6.5% (n=199) Usual Care @ 47wkb,c,o NCT04873934 · Phase 3 · registry result, not featured evidence · combination 1 other source trial69.8% (n=225) vs 5.3% (n=225) Usual Care @ 47wk NCT04929249 · Phase 3 · registry result, not featured evidence |
| LDL-C Less Than 100 responder rate · % of participants | 88.1% (n=52) vs 32.2% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2Wb,c,o NCT01644474 · Phase 3 | 80.5% (n=77) vs 32.1% (n=81) Usual Care @ 47wkb,c,o NCT04929249 · Phase 3 · registry result, not featured evidence |
| LDL-C Less Than 70 responder rate · % of participants | 64.5% (n=1058) vs 10.7% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2Wa,b,c,p NCT02957682 · Phase 4 · registry result, not featured evidence | 66.7% (n=201) vs 28.1% (n=199) Usual Care @ 47wka,b,c,p NCT04873934 · Phase 3 · registry result, not featured evidence · combination 1 other source trial81.8% (n=225) vs 22.2% (n=225) Usual Care @ 47wk NCT04929249 · Phase 3 · registry result, not featured evidence |
| Lp(a percent change · % of baseline No placebo or comparator arm | -29.2% (n=651) @ 168wk75 or 150 mg Q2Wg,e,c,h NCT01954394 · Phase 3 · registry result, not featured evidence | -5.24% (n=277) @ 205.71wkg,e,c,h NCT03060577 · Phase 2 · registry result, not featured evidence |
| Non-HDL-C percent change · % of baseline No placebo or comparator arm | -47.7% (n=651) @ 168wk75 or 150 mg Q2We,c,f NCT01954394 · Phase 3 · registry result, not featured evidence | -13% (n=13) @ 102.86wke,c,f NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 1 other source trial-5% (n=34) @ 102.86wk NCT03851705 · Phase 3 · registry result, not featured evidence |
| Non-HDL-C Change mg/dL absolute change · mg/dL | -69.2 vs -20.3 Standard of Care mg/dL @ 36wka,b,c,i NCT02984982 · Phase 4 · registry result, not featured evidence | -49.7 vs -3 placebo mg/dL @ 51.43wka,b,c,i NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
| Non-HDL-C Change mg/dL absolute change · mg/dL No placebo or comparator arm | -106.4 mg/dL @ 8wk300 mg Q4Wj,l,e,c,m NCT02890992 · Phase 2 · registry result, not featured evidence show 7 more doses-0.6 mg/dL @ 8wk150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence -63.1 mg/dL @ 8wk150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence -88.5 mg/dL @ 8wk75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence -29.5 mg/dL @ 8wk75 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence -28.7 mg/dL @ 8wk50 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence -62.7 mg/dL @ 8wk40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence -86.1 mg/dL @ 8wk30 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence | -9.3 mg/dL @ 102.86wkl,e,c,m NCT03851705 · Phase 3 · registry result, not featured evidence |
| Total Cholesterol percent change · % of baseline | -35.43% (n=93) vs -7.59% (n=89) Standard of Care @ 36wka,b,c,q NCT02984982 · Phase 4 · registry result, not featured evidence | -28% (n=810) vs 1.79% (n=807) placebo @ 72.9wka,b,c,q NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 1 other source trial-33.56% (n=781) vs -0.42% (n=781) placebo @ 72.9wk NCT03399370 · Phase 3 |
| Total Cholesterol percent change · % of baseline No placebo or comparator arm | -39.1% (n=651) @ 168wk75 or 150 mg Q2We,c,f NCT01954394 · Phase 3 · registry result, not featured evidence | -2.9% (n=34) @ 102.86wke,c,f NCT03851705 · Phase 3 · registry result, not featured evidence |
| Total Cholesterol Change mg/dL absolute change · mg/dL | -61.7 vs -15.2 Standard of Care mg/dL @ 36wka,b,c,i NCT02984982 · Phase 4 · registry result, not featured evidence | -48.2 vs -3.1 placebo mg/dL @ 51.43wka,b,c,i NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
| Total Cholesterol Change mg/dL absolute change · mg/dL No placebo or comparator arm | -105.1 mg/dL @ 8wk300 mg Q4Wj,l,e,c,m NCT02890992 · Phase 2 · registry result, not featured evidence show 7 more doses5.3 mg/dL @ 8wk150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence -60.7 mg/dL @ 8wk150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence -84.4 mg/dL @ 8wk75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence -27.2 mg/dL @ 8wk75 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence -20.8 mg/dL @ 8wk50 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence -57.1 mg/dL @ 8wk40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence -80.1 mg/dL @ 8wk30 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence | -8.5 mg/dL @ 102.86wkl,e,c,m NCT03851705 · Phase 3 · registry result, not featured evidence |
| Triglycerides percent change · % of baseline | -2.4% (n=41) vs 4.1% (n=21) placebo @ 18wk150 mg Q2Wb,c,r NCT02326220 · Phase 3 | 1.7% (n=92) vs 3.8% (n=48) placebo @ 51.43wkb,c,r NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
| Triglycerides percent change · % of baseline No placebo or comparator arm | -8.28% (n=921) @ 12wkg,e,c,s NCT02476006 · Phase 3 · registry result, not featured evidence | 0.73% (n=277) @ 205.71wkg,e,c,s NCT03060577 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 28.3%150 mg Q2Wt NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 84 more results40.3%150 mg Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 —150 Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 —75 /up to 150 mg Q2W NCT01644175 · Phase 3 25.4%75/150 mg Q2W NCT01644175 · Phase 3 —75/Up to 150 mg Q2W NCT01623115 · Phase 3 23.8%75 mg/Up to 150 mg Q2W NCT01623115 · Phase 3 n/a: no completion milestone75 mg/up to 150 mg NCT01709500 · Phase 3 —300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 12.8%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 28.1%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 —75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 16.7%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 21.6%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 9.8%150 mg Q2W NCT02326220 · Phase 3 25.5%75 /up to 150 mg Q2W NCT01644188 · Phase 3 —75/Up to 150 mg Q2W NCT01644188 · Phase 3 15.4%75/Up to 150 mg Q2W NCT01644474 · Phase 3 —75/Up150 mg Q2W NCT01644474 · Phase 3 0%150 mg SC Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 8.2%Q2W NCT03510884 · Phase 3 5.8%Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 0%Q2W NCT03510884 · Phase 3 3.7%Q4W NCT03510884 · Phase 3 22%75 mg Q2W/Up to 150 mg Q2W NCT01663402 · Phase 3 —Alirocumab NCT01663402 · Phase 3 15.5%75 Q2W/Up150 Q2W NCT02957682 · Phase 4 · registry result, not featured evidence 0% NCT02938949 · Phase 4 · registry result, not featured evidence 9.6% NCT02984982 · Phase 4 · registry result, not featured evidence 11.2%75 mg Q2W/Up to 150 mg Q2W NCT02642159 · Phase 4 · registry result, not featured evidence 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 12% NCT02476006 · Phase 3 · registry result, not featured evidence —New Auto-Injector Device (Parallel NCT03415178 · Phase 3 · registry result, not featured evidence —New Auto-Injector Device (Single-a NCT03415178 · Phase 3 · registry result, not featured evidence 5.7%New Auto-injector Device (SYDNEY) NCT03415178 · Phase 3 · registry result, not featured evidence 6.6%75 mg Q2W/up to 150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence —75 mg Q2W/up150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence 3.8%150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 0%150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 8.7%75 or 150 mg Q2W NCT01954394 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence 15.3%150 mg Q4W/Up to 150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence —75 mg Q2W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 23.8%75 mg/ up to 150 mg NCT01709513 · Phase 3 · registry result, not featured evidence 9.6%75 mg Q2W/Up to 150 mg Q2W NCT02585778 · Phase 3 · registry result, not featured evidence 10.3%75 mg Q2W/Up to 150 mg Q2W NCT02289963 · Phase 3 · registry result, not featured evidence —75 mg/ Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 8.3%75 mg/Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 22.4%75 mg/up to 150 mg + 10 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 24.1%75 mg/up to 150 mg + 20 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 19.3%75 mg/up to 150 mg + Atorvastatin 20 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 19.1%75 mg/up to 150 mg + Atorvastatin 40 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 0%300 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%50 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%30 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm/ApoB LOFm: Alirocumab F NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm: Alirocumab From Day 1 NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm: Alirocumab From Day 15 NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence 41.3% NCT01576484 · Phase 2 · registry result, not featured evidence | 2.9%u NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 46 more results—Part 1 - Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 2.2%Part 1- Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 0%Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 4.7% NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 7.7% NCT03399370 · Phase 3 2% NCT05192941 · Phase 4 · registry result, not featured evidence 2.9%Inclisiran - Inclisiran NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran - Inclisiran: Core Part NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran - Inclisiran: Extension NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran + Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 9%Inclisiran With Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 5.7% NCT05763875 · Phase 3 · registry result, not featured evidence 5.8% NCT04929249 · Phase 3 · registry result, not featured evidence 100%ORION-3 Rollover NCT03814187 · Phase 3 · registry result, not featured evidence 17.6%Phase III Inclisiran-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 18.8%Phase III Placebo-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 16.8%Inclisiran NCT04807400 · Phase 3 · registry result, not featured evidence 15.2%Inclisiran + BS NCT04807400 · Phase 3 · registry result, not featured evidence · combination 8.1%Part 1 - Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 1: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence 4%300 mg NCT04666298 · Phase 2 · registry result, not featured evidence —300 mg NCT04666298 · Phase 2 · registry result, not featured evidence 1%200 mg NCT04666298 · Phase 2 · registry result, not featured evidence —200 mg NCT04666298 · Phase 2 · registry result, not featured evidence 0%100 mg NCT04666298 · Phase 2 · registry result, not featured evidence —100 mg NCT04666298 · Phase 2 · registry result, not featured evidence —Inclisiran Only Arm NCT03060577 · Phase 2 · registry result, not featured evidence 19.7%Inclisiran-only NCT03060577 · Phase 2 · registry result, not featured evidence —Switching Arm After Day 360 Visit NCT03060577 · Phase 2 · registry result, not featured evidence 55.6% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy —300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 6.6%300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 4.8%300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 12.1%500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 6.3%200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 1.7%200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 8.1%100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 7.3%150 mg Q2Wt NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 84 more results4.2%150 mg Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 —150 Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 —75 /up to 150 mg Q2W NCT01644175 · Phase 3 6.2%75/150 mg Q2W NCT01644175 · Phase 3 —75/Up to 150 mg Q2W NCT01623115 · Phase 3 4%75 mg/Up to 150 mg Q2W NCT01623115 · Phase 3 3%75 mg/up to 150 mg NCT01709500 · Phase 3 —300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 5.4%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 9.6%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 —75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 5.1%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 8.1%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 4.9%150 mg Q2W NCT02326220 · Phase 3 9.2%75 /up to 150 mg Q2W NCT01644188 · Phase 3 —75/Up to 150 mg Q2W NCT01644188 · Phase 3 9.6%75/Up to 150 mg Q2W NCT01644474 · Phase 3 —75/Up150 mg Q2W NCT01644474 · Phase 3 —150 mg SC Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 0%Q2W NCT03510884 · Phase 3 3.8%Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 0%Q2W NCT03510884 · Phase 3 0%Q4W NCT03510884 · Phase 3 3.8%75 mg Q2W/Up to 150 mg Q2W NCT01663402 · Phase 3 —Alirocumab NCT01663402 · Phase 3 6.2%75 Q2W/Up150 Q2W NCT02957682 · Phase 4 · registry result, not featured evidence — NCT02938949 · Phase 4 · registry result, not featured evidence 4.8% NCT02984982 · Phase 4 · registry result, not featured evidence 3.6%75 mg Q2W/Up to 150 mg Q2W NCT02642159 · Phase 4 · registry result, not featured evidence 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 4.1% NCT02476006 · Phase 3 · registry result, not featured evidence —New Auto-Injector Device (Parallel NCT03415178 · Phase 3 · registry result, not featured evidence —New Auto-Injector Device (Single-a NCT03415178 · Phase 3 · registry result, not featured evidence —New Auto-injector Device (SYDNEY) NCT03415178 · Phase 3 · registry result, not featured evidence 1.5%75 mg Q2W/up to 150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence —75 mg Q2W/up150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence 1.9%150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 0%150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 3.5%75 or 150 mg Q2W NCT01954394 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence 8.5%150 mg Q4W/Up to 150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence —75 mg Q2W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 18.3%75 mg/ up to 150 mg NCT01709513 · Phase 3 · registry result, not featured evidence 4.9%75 mg Q2W/Up to 150 mg Q2W NCT02585778 · Phase 3 · registry result, not featured evidence 2.1%75 mg Q2W/Up to 150 mg Q2W NCT02289963 · Phase 3 · registry result, not featured evidence —75 mg/ Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 4.9%75 mg/Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 6.1%75 mg/up to 150 mg + 10 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 3.7%75 mg/up to 150 mg + 20 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 8.8%75 mg/up to 150 mg + Atorvastatin 20 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 4.3%75 mg/up to 150 mg + Atorvastatin 40 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination —300 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —75 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —50 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —30 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —PCSK9 GOFm/ApoB LOFm: Alirocumab F NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9 GOFm: Alirocumab From Day 1 NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9 GOFm: Alirocumab From Day 15 NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence 2.2% NCT01576484 · Phase 2 · registry result, not featured evidence | —u NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 46 more results—Part 1 - Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —Part 1- Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 — NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 — NCT03399370 · Phase 3 0.3% NCT05192941 · Phase 4 · registry result, not featured evidence —Inclisiran - Inclisiran NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran - Inclisiran: Core Part NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran - Inclisiran: Extension NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran + Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 0%Inclisiran With Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 0.6% NCT05763875 · Phase 3 · registry result, not featured evidence 0.9% NCT04929249 · Phase 3 · registry result, not featured evidence 0%ORION-3 Rollover NCT03814187 · Phase 3 · registry result, not featured evidence 1.5%Phase III Inclisiran-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 1.6%Phase III Placebo-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 0.7%Inclisiran NCT04807400 · Phase 3 · registry result, not featured evidence 1%Inclisiran + BS NCT04807400 · Phase 3 · registry result, not featured evidence · combination —Part 1 - Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 1: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —300 mg NCT04666298 · Phase 2 · registry result, not featured evidence —300 mg NCT04666298 · Phase 2 · registry result, not featured evidence —200 mg NCT04666298 · Phase 2 · registry result, not featured evidence —200 mg NCT04666298 · Phase 2 · registry result, not featured evidence —100 mg NCT04666298 · Phase 2 · registry result, not featured evidence —100 mg NCT04666298 · Phase 2 · registry result, not featured evidence —Inclisiran Only Arm NCT03060577 · Phase 2 · registry result, not featured evidence 3.1%Inclisiran-only NCT03060577 · Phase 2 · registry result, not featured evidence —Switching Arm After Day 360 Visit NCT03060577 · Phase 2 · registry result, not featured evidence — NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy —300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 18.7%150 mg Q2Wt NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 84 more results—150 mg Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 13.9%150 Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 12.6%75 /up to 150 mg Q2W NCT01644175 · Phase 3 —75/150 mg Q2W NCT01644175 · Phase 3 13.7%75/Up to 150 mg Q2W NCT01623115 · Phase 3 —75 mg/Up to 150 mg Q2W NCT01623115 · Phase 3 6%75 mg/up to 150 mg NCT01709500 · Phase 3 11.6%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 —300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 —300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 11.3%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 —75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 —75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 9.8%150 mg Q2W NCT02326220 · Phase 3 3.4%150 mg Q2W NCT02326220 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 —75 /up to 150 mg Q2W NCT01644188 · Phase 3 25.9%75/Up to 150 mg Q2W NCT01644188 · Phase 3 —75/Up to 150 mg Q2W NCT01644474 · Phase 3 1.9%75/Up150 mg Q2W NCT01644474 · Phase 3 —150 mg SC Q2W NCT03156621 · Phase 3 0%150 Q2W NCT03156621 · Phase 3 2.2%150 Q2W NCT03156621 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 8.2%Q2W NCT03510884 · Phase 3 3.8%Q4W NCT03510884 · Phase 3 8.7%Q2W NCT03510884 · Phase 3 6.1%Q4W NCT03510884 · Phase 3 0%Q2W NCT03510884 · Phase 3 8%Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —75 mg Q2W/Up to 150 mg Q2W NCT01663402 · Phase 3 23.3%Alirocumab NCT01663402 · Phase 3 17.4%75 Q2W/Up150 Q2W NCT02957682 · Phase 4 · registry result, not featured evidence 40% NCT02938949 · Phase 4 · registry result, not featured evidence 18.4% NCT02984982 · Phase 4 · registry result, not featured evidence 9.5%75 mg Q2W/Up to 150 mg Q2W NCT02642159 · Phase 4 · registry result, not featured evidence 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 16.2% NCT02476006 · Phase 3 · registry result, not featured evidence 3%New Auto-Injector Device (Parallel NCT03415178 · Phase 3 · registry result, not featured evidence 3%New Auto-Injector Device (Single-a NCT03415178 · Phase 3 · registry result, not featured evidence —New Auto-injector Device (SYDNEY) NCT03415178 · Phase 3 · registry result, not featured evidence —75 mg Q2W/up to 150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence 10.1%75 mg Q2W/up150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence —150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence 3.8%150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 1.9%150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence 7.6%150 mg Q4W/Up Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 22%75 or 150 mg Q2W NCT01954394 · Phase 3 · registry result, not featured evidence 29.2%150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence 26.4%150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence 29.4%150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up to 150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 12.1%150 mg Q4W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 6.1%75 mg Q2W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 9.5%75 mg/ up to 150 mg NCT01709513 · Phase 3 · registry result, not featured evidence 9%75 mg Q2W/Up to 150 mg Q2W NCT02585778 · Phase 3 · registry result, not featured evidence 17.5%75 mg Q2W/Up to 150 mg Q2W NCT02289963 · Phase 3 · registry result, not featured evidence 7%75 mg/ Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence —75 mg/Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 4.1%75 mg/up to 150 mg + 10 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 7.4%75 mg/up to 150 mg + 20 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 5.3%75 mg/up to 150 mg + Atorvastatin 20 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 2.1%75 mg/up to 150 mg + Atorvastatin 40 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 0%300 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%50 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%30 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm/ApoB LOFm: Alirocumab F NCT01604824 · Phase 2 · registry result, not featured evidence 16.7%PCSK9 GOFm: Alirocumab From Day 1 NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm: Alirocumab From Day 15 NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence 17.4% NCT01576484 · Phase 2 · registry result, not featured evidence | 7.5%u NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 46 more results3.2%Part 1 - Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —Part 1- Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 0%Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 0%Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 22.3% NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 22.4% NCT03399370 · Phase 3 16.4% NCT05192941 · Phase 4 · registry result, not featured evidence —Inclisiran - Inclisiran NCT05888103 · Phase 3 · registry result, not featured evidence 4.9%Inclisiran - Inclisiran: Core Part NCT05888103 · Phase 3 · registry result, not featured evidence 1%Inclisiran - Inclisiran: Extension NCT05888103 · Phase 3 · registry result, not featured evidence 15.8%Inclisiran + Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination —Inclisiran With Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 0.6% NCT05763875 · Phase 3 · registry result, not featured evidence 11.5% NCT04929249 · Phase 3 · registry result, not featured evidence 15.1%ORION-3 Rollover NCT03814187 · Phase 3 · registry result, not featured evidence 30.7%Phase III Inclisiran-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 32.6%Phase III Placebo-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 8.8%Inclisiran NCT04807400 · Phase 3 · registry result, not featured evidence 12.8%Inclisiran + BS NCT04807400 · Phase 3 · registry result, not featured evidence · combination —Part 1 - Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence 5.4%Part 1: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence 20.8%Part 2: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —300 mg NCT04666298 · Phase 2 · registry result, not featured evidence 7.1%300 mg NCT04666298 · Phase 2 · registry result, not featured evidence —200 mg NCT04666298 · Phase 2 · registry result, not featured evidence 6.9%200 mg NCT04666298 · Phase 2 · registry result, not featured evidence —100 mg NCT04666298 · Phase 2 · registry result, not featured evidence 3.6%100 mg NCT04666298 · Phase 2 · registry result, not featured evidence 36.6%Inclisiran Only Arm NCT03060577 · Phase 2 · registry result, not featured evidence —Inclisiran-only NCT03060577 · Phase 2 · registry result, not featured evidence 34.5%Switching Arm After Day 360 Visit NCT03060577 · Phase 2 · registry result, not featured evidence 25% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy 14.8%300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 18%300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 12.3%500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 12.9%200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 18.3%200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 21.3%100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 150 mg Q2Wt nasopharyngitis 13.5% (placebo 13.1%) upper respiratory tract infection 7.4% (placebo 8.6%) injection site reaction 5.9% (placebo 4.2%) NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 60 more results150 Q2W nasopharyngitis 13.9% (placebo 11.4%) influenza 12.5% (placebo 2.9%) injection site reaction 8.3% (placebo 5.7%) NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 75 /up to 150 mg Q2W upper respiratory tract infection 7.7% (placebo 10.3%) nasopharyngitis 7.2% (placebo 4.7%) urinary tract infection 6.3% (placebo 3.7%) NCT01644175 · Phase 3 75/Up to 150 mg Q2W injection site reaction 12.4% (placebo 11%) nasopharyngitis 11.2% (placebo 7.4%) upper respiratory tract infection 6.8% (placebo 8.6%) NCT01623115 · Phase 3 75 mg/up to 150 mg influenza 14.4% (placebo 7.4%) injection site reaction 10.8% (placebo 7.4%) nasopharyngitis 10.8% (placebo 19.8%) NCT01709500 · Phase 3 300 mg Q4W/Up 150 mg Q2W injection site reaction 16.2% (placebo 7%) upper respiratory tract infection 9% (placebo 7.9%) nasopharyngitis 8.5% (placebo 7.9%) NCT01926782 · Phase 3 75 mg Q2W/Up 150 mg Q2W injection site reaction 8.7% (placebo 7%) nasopharyngitis 8.7% (placebo 7.9%) upper respiratory tract infection 7% (placebo 7.9%) NCT01926782 · Phase 3 150 mg Q2W fatigue 14.6% (placebo 9.5%) myalgia 12.2% (placebo 4.8%) diarrhoea 9.8% (placebo 0%) NCT02326220 · Phase 3 150 mg Q2W anaemia 6.9% (placebo 0%) nasopharyngitis 3.4% (placebo 9.5%) arthralgia 0% (placebo 9.5%) NCT02326220 · Phase 3 75/Up to 150 mg Q2W accidental overdose 9.8% upper respiratory tract infection 8.8% hypertension 6.5% NCT01644188 · Phase 3 150 Q2W diarrhoea 6.7% (placebo 0%) headache 4.4% (placebo 8.3%) nasopharyngitis 4.4% (placebo 0%) NCT03156621 · Phase 3 150 Q2W nasopharyngitis 6.7% (placebo 0%) diarrhoea 2.2% (placebo 0%) headache 2.2% (placebo 8.3%) NCT03156621 · Phase 3 Q2W nasopharyngitis 14.3% (placebo 8%) headache 6.1% (placebo 8%) injection site reaction 6.1% (placebo 0%) NCT03510884 · Phase 3 Q4W headache 7.7% (placebo 8%) upper respiratory tract infection 5.8% (placebo 12%) injection site reaction 3.8% (placebo 0%) NCT03510884 · Phase 3 Q2W headache 10.9% (placebo 8%) oropharyngeal pain 8.7% (placebo 0%) injection site reaction 6.5% (placebo 0%) NCT03510884 · Phase 3 Q4W headache 14.3% (placebo 8%) covid-19 8.2% (placebo 0%) nasopharyngitis 6.1% (placebo 8%) NCT03510884 · Phase 3 Q2W low density lipoprotein decreased 8% (placebo 0%) nasopharyngitis 8% (placebo 8%) nausea 8% (placebo 0%) NCT03510884 · Phase 3 Q4W headache 16% (placebo 8%) covid-19 4% (placebo 0%) injection site reaction 4% (placebo 0%) NCT03510884 · Phase 3 nasopharyngitis 6% (placebo 5.6%) hypertension 5.7% (placebo 6.1%) myalgia 5.5% (placebo 5.3%) NCT01663402 · Phase 3 75 Q2W/Up150 Q2W nasopharyngitis 7.5% (placebo 8.2%) headache 6.5% (placebo 7.8%) hypertension 5.9% (placebo 6.7%) NCT02957682 · Phase 4 · registry result, not featured evidence nasopharyngitis 26.2% injection site reaction 6.8% back pain 5.8% NCT02984982 · Phase 4 · registry result, not featured evidence 75 mg Q2W/Up to 150 mg Q2W urinary tract infection 5.5% diarrhoea 5.1% arthralgia 2.2% NCT02642159 · Phase 4 · registry result, not featured evidence 150 mg Q2W nasopharyngitis 22.2% alanine aminotransferase increased 11.1% aortic valve incompetence 11.1% NCT03510715 · Phase 3 · registry result, not featured evidence 75 mg Q2W/up to 150 mg Q2W aortic valve incompetence 22.2% headache 22.2% influenza 22.2% NCT03510715 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.8% myalgia 7.1% headache 6.1% NCT02476006 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 9.1% arthralgia 6.1% contusion 3% NCT03415178 · Phase 3 · registry result, not featured evidence urinary tract infection 6.1% arthralgia 4.5% contusion 1.5% NCT03415178 · Phase 3 · registry result, not featured evidence 75 mg Q2W/up150 mg Q2W upper respiratory tract infection 13.3% accidental overdose 6.7% NCT02715726 · Phase 3 · registry result, not featured evidence 150 mg Q2W viral upper respiratory tract infection 15.1% (placebo 16.1%) non-cardiac chest pain 7.5% (placebo 1.8%) back pain 1.9% (placebo 0%) NCT02584504 · Phase 3 · registry result, not featured evidence 150 mg Q4W viral upper respiratory tract infection 14.8% (placebo 16.1%) pharyngitis 5.6% (placebo 0%) back pain 0% (placebo 0%) NCT02584504 · Phase 3 · registry result, not featured evidence 150 mg Q4W/Up Q2W viral upper respiratory tract infection 34.2% (placebo 16.1%) fall 7% (placebo 5.4%) back pain 5.1% (placebo 0%) NCT02584504 · Phase 3 · registry result, not featured evidence 75 or 150 mg Q2W viral upper respiratory tract infection 14.2% upper respiratory tract infection 10.8% influenza 9.3% NCT01954394 · Phase 3 · registry result, not featured evidence 150 mg Q4W viral upper respiratory tract infection 18.8% (placebo 5.2%) back pain 14.6% (placebo 0%) injection site reaction 14.6% (placebo 0%) NCT02023879 · Phase 3 · registry result, not featured evidence 150 mg Q4W viral upper respiratory tract infection 15.1% (placebo 5.2%) fall 13.2% (placebo 1.7%) diarrhoea 10.4% (placebo 3.4%) NCT02023879 · Phase 3 · registry result, not featured evidence 150 mg Q4W cough 17.6% (placebo 0%) arthralgia 15.7% (placebo 6.9%) osteoarthritis 15.7% (placebo 3.4%) NCT02023879 · Phase 3 · registry result, not featured evidence 150 mg Q4W/Up150 mg Q2W injection site reaction 13.8% (placebo 0%) arthralgia 12.1% (placebo 6.9%) headache 8.6% (placebo 6.9%) NCT02023879 · Phase 3 · registry result, not featured evidence 75 mg Q2W/Up150 mg Q2W headache 8.7% (placebo 6.9%) viral upper respiratory tract infection 8.7% (placebo 5.2%) muscle spasms 7.8% (placebo 0%) NCT02023879 · Phase 3 · registry result, not featured evidence 75 mg/ up to 150 mg myalgia 24.6% nasopharyngitis 6.3% upper respiratory tract infection 5.6% NCT01709513 · Phase 3 · registry result, not featured evidence 75 mg Q2W/Up to 150 mg Q2W nasopharyngitis 4.9% (placebo 5.3%) NCT02585778 · Phase 3 · registry result, not featured evidence 75 mg Q2W/Up to 150 mg Q2W dizziness 6.2% (placebo 2.9%) nasopharyngitis 6.2% (placebo 3.9%) diarrhoea 5.2% (placebo 1%) NCT02289963 · Phase 3 · registry result, not featured evidence 75 mg/ Up to 150 mg Q2W nasopharyngitis 45.5% (placebo 36.1%) back pain 12.6% (placebo 5.6%) injection site reaction 12.6% (placebo 4.2%) NCT02107898 · Phase 3 · registry result, not featured evidence 75 mg/up to 150 mg + 10 mg arthralgia 8.2% nausea 6.1% nasopharyngitis 4.1% NCT01730053 · Phase 3 · registry result, not featured evidence · combination 75 mg/up to 150 mg + 20 mg myalgia 7.4% upper respiratory tract infection 7.4% injection site reaction 5.6% NCT01730053 · Phase 3 · registry result, not featured evidence · combination 75 mg/up to 150 mg + Atorvastatin 20 mg muscle spasms 7% back pain 5.3% arthralgia 3.5% NCT01730040 · Phase 3 · registry result, not featured evidence · combination 75 mg/up to 150 mg + Atorvastatin 40 mg back pain 8.5% nasopharyngitis 8.5% accidental overdose 6.4% NCT01730040 · Phase 3 · registry result, not featured evidence · combination 300 mg Q4W acne 20% diarrhoea 20% influenza like illness 20% NCT02890992 · Phase 2 · registry result, not featured evidence 150 mg Q4W nasopharyngitis 20% pyogenic granuloma 20% upper respiratory tract infection 20% NCT02890992 · Phase 2 · registry result, not featured evidence 150 mg Q4W abdominal discomfort 16.7% diarrhoea 16.7% epistaxis 16.7% NCT02890992 · Phase 2 · registry result, not featured evidence 75 mg Q2W ligament sprain 11.1% nasopharyngitis 11.1% abdominal pain 5.6% NCT02890992 · Phase 2 · registry result, not featured evidence 75 mg Q2W animal scratch 16.7% arthropod bite 16.7% blood follicle stimulating hormone decreased 16.7% NCT02890992 · Phase 2 · registry result, not featured evidence 75 mg Q4W abdominal pain 16.7% asthma 16.7% depressed mood 16.7% NCT02890992 · Phase 2 · registry result, not featured evidence 50 mg Q2W diarrhoea 33.3% nasopharyngitis 33.3% alcohol abuse 16.7% NCT02890992 · Phase 2 · registry result, not featured evidence 40 mg Q2W gastroenteritis viral 30% ear infection 10% headache 10% NCT02890992 · Phase 2 · registry result, not featured evidence 40 mg Q2W pharyngitis 25% abdominal discomfort 0% abdominal pain 0% NCT02890992 · Phase 2 · registry result, not featured evidence 30 mg Q2W ear infection 25% epistaxis 25% fall 25% NCT02890992 · Phase 2 · registry result, not featured evidence viral upper respiratory tract infection 40% acne 20% blood bilirubin increased 20% NCT01604824 · Phase 2 · registry result, not featured evidence gastroenteritis 33.3% viral upper respiratory tract infection 33.3% abdominal discomfort 16.7% NCT01604824 · Phase 2 · registry result, not featured evidence headache 28.6% acne 14.3% angina pectoris 14.3% NCT01604824 · Phase 2 · registry result, not featured evidence abdominal discomfort 20% abdominal distension 20% acne 20% NCT01604824 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 28.3% nasopharyngitis 23.9% bronchitis 21.7% NCT01576484 · Phase 2 · registry result, not featured evidence | u nasopharyngitis 11.6% (placebo 8.3%) injection site reaction 9.1% (placebo 0%) back pain 7.1% (placebo 4.2%) NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 30 more resultscovid-19 18.3% (placebo 25%) nasopharyngitis 14% (placebo 18.8%) headache 12.9% (placebo 6.3%) NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 covid-19 44.4% (placebo 25%) abdominal pain upper 22.2% (placebo 0%) injection site reaction 22.2% (placebo 0%) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 headache 15.4% (placebo 0%) influenza 15.4% (placebo 0%) abdominal pain upper 7.7% (placebo 0%) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 nasopharyngitis 11.2% (placebo 11.2%) diabetes mellitus 10.9% (placebo 11.7%) hypertension 6.5% (placebo 6.7%) NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 diabetes mellitus 15.4% (placebo 13.9%) bronchitis 5.9% (placebo 3.9%) hypertension 5.4% (placebo 5.4%) NCT03399370 · Phase 3 nasopharyngitis 8.2% (placebo 9.1%) covid-19 6.1% (placebo 6.3%) diabetes mellitus inadequate control 6.1% (placebo 5.6%) NCT05192941 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 24.3% (placebo 16.3%) blood glucose increased 9.7% (placebo 6.7%) blood creatine phosphokinase increased 6.8% (placebo 5.8%) NCT05888103 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 14% (placebo 16.3%) blood creatine phosphokinase increased 6% (placebo 5.8%) alanine aminotransferase increased 5% (placebo 2.9%) NCT05888103 · Phase 3 · registry result, not featured evidence covid-19 4.9% injection site pain 4.9% arthralgia 3.9% NCT04873934 · Phase 3 · registry result, not featured evidence · combination headache 3.4% (placebo 0%) nasopharyngitis 3.4% (placebo 3.4%) urinary tract infection 1.7% (placebo 2.3%) NCT05763875 · Phase 3 · registry result, not featured evidence covid-19 7.7% injection site pain 7.7% blood creatine phosphokinase increased 4.3% NCT04929249 · Phase 3 · registry result, not featured evidence covid-19 18.3% urinary tract infection 3.5% hypertension 3.2% NCT03814187 · Phase 3 · registry result, not featured evidence covid-19 11.8% diabetes mellitus inadequate control 7.5% hypertension 7% NCT03814187 · Phase 3 · registry result, not featured evidence covid-19 11.9% diabetes mellitus inadequate control 7.4% hypertension 7.4% NCT03814187 · Phase 3 · registry result, not featured evidence back pain 0.4% injection site rash 0.4% muscle spasms 0.4% NCT04807400 · Phase 3 · registry result, not featured evidence dizziness 0.4% rash 0.4% back pain 0% NCT04807400 · Phase 3 · registry result, not featured evidence · combination diarrhoea 5.4% (placebo 0%) pyrexia 5.4% (placebo 0%) respiratory tract infection viral 5.4% (placebo 10.5%) NCT03851705 · Phase 3 · registry result, not featured evidence corona virus infection 7.5% (placebo 0%) international normalised ratio increased 5.7% (placebo 0%) activated partial thromboplastin time prolonged 3.8% (placebo 0%) NCT03851705 · Phase 3 · registry result, not featured evidence 300 mg pyrexia 18.2% (placebo 12.3%) diabetes mellitus inadequate control 15.2% (placebo 15.8%) diabetes mellitus 12.1% (placebo 8.8%) NCT04666298 · Phase 2 · registry result, not featured evidence 200 mg diabetes mellitus 11.9% (placebo 8.8%) injection site reaction 11.9% (placebo 3.5%) pyrexia 11.9% (placebo 12.3%) NCT04666298 · Phase 2 · registry result, not featured evidence 100 mg diabetes mellitus 20% (placebo 8.8%) covid-19 14.5% (placebo 3.5%) pyrexia 14.5% (placebo 12.3%) NCT04666298 · Phase 2 · registry result, not featured evidence nasopharyngitis 19.4% (placebo 6.7%) hypertension 14.8% (placebo 2.2%) arthralgia 14.1% (placebo 11.1%) NCT03060577 · Phase 2 · registry result, not featured evidence hypertension 19.5% (placebo 2.2%) back pain 14.9% (placebo 1.1%) nasopharyngitis 14.9% (placebo 6.7%) NCT03060577 · Phase 2 · registry result, not featured evidence abdominal pain upper 25% acne 25% angina unstable 25% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy 300 mg double dose nasopharyngitis 18% (placebo 12.9%) musculoskeletal pain 9.8% (placebo 6.5%) diarrhoea 8.2% (placebo 3.2%) NCT02597127 · Phase 2 · registry result, not featured evidence 300 mg single dose nasopharyngitis 14.8% (placebo 12.9%) cough 11.5% (placebo 4.8%) myalgia 9.8% (placebo 4.8%) NCT02597127 · Phase 2 · registry result, not featured evidence 500 mg single dose nasopharyngitis 13.8% (placebo 12.9%) influenza 7.7% (placebo 3.2%) upper respiratory tract infection 7.7% (placebo 3.2%) NCT02597127 · Phase 2 · registry result, not featured evidence 200 mg double dose diarrhoea 11.3% (placebo 3.2%) cough 9.7% (placebo 4.8%) arthralgia 8.1% (placebo 1.6%) NCT02597127 · Phase 2 · registry result, not featured evidence 200 mg single dose nasopharyngitis 13.3% (placebo 12.9%) arthralgia 6.7% (placebo 1.6%) back pain 6.7% (placebo 3.2%) NCT02597127 · Phase 2 · registry result, not featured evidence 100 mg double dose nasopharyngitis 13.1% (placebo 12.9%) myalgia 11.5% (placebo 4.8%) back pain 9.8% (placebo 3.2%) NCT02597127 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 96 weeks versus 51.43 weeks.
- ePopulation context differs: registered conditions differ.
- fAssessment timepoints differ: 168 weeks versus 102.86 weeks.
- gTrial phases differ: Phase 3 versus Phase 2.
- hAssessment timepoints differ: 168 weeks versus 205.71 weeks.
- iAssessment timepoints differ: 36 weeks versus 51.43 weeks.
- jThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- kAssessment timepoints differ: 8 weeks versus 205.71 weeks.
- lTrial phases differ: Phase 2 versus Phase 3.
- mAssessment timepoints differ: 8 weeks versus 102.86 weeks.
- nAssessment timepoints differ: 208 weeks versus 47.14 weeks.
- oAssessment timepoints differ: 24 weeks versus 47 weeks.
- pAssessment timepoints differ: 96 weeks versus 47 weeks.
- qAssessment timepoints differ: 36 weeks versus 72.9 weeks.
- rAssessment timepoints differ: 18 weeks versus 51.43 weeks.
- sAssessment timepoints differ: 12 weeks versus 205.71 weeks.
- tPopulation comparability has not been reviewed for 82 of these studies.
- uPopulation comparability has not been reviewed for 40 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alirocumab
show 36 more results
show 25 more results
show 1 more result
show 53 more results
show 7 more results
show 1 more result
show 10 more results
show 1 more result
show 8 more results
show 7 more results
+ 61 further endpoints in the CSV export.
Inclisiran
show 6 more results
show 2 more results
show 29 more results
show 5 more results
+ 26 further endpoints in the CSV export.
Homozygous Familial Hypercholesterolemia
Shared mechanism: PCSK9 · full Homozygous Familial Hypercholesterolemia pipeline
Alirocumab · Praluent
Marketed by Regeneron Pharmaceuticals and partners
NCT03156621 · Phase 3 · completed
The trial randomized 69 participants 2:1 to triple-blinded alirocumab or matching placebo, and its primary LDL-cholesterol endpoint was met, with a statistically significant difference favoring alirocumab (p<0.0001). The record does not report a power or sample-size calculation, so the study provides meaningful but limited evidence despite its strong randomized and blinded design.
Reported efficacy
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand): Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) (Baseline to Week 12): Alirocumab 150 mg SC Q2W -26.9 Percentage of change (Standard Error 4.6) vs Placebo in DBTP 8.6 Percentage of change (Standard Error 6.3) (met)
Result source: NCT03156621
Inclisiran · Leqvio
Marketed by Novartis and partners
NCT04659863 · Phase 3 · completed
The first year was randomized, double-blind, and placebo-controlled, with 9 participants receiving inclisiran and 4 receiving placebo. The primary LDL-C endpoint was met, but the total sample of 13 was very small and underpowered for reliable generalization, so the findings provide limited evidence despite the favorable result.
Next expected readout: March 2028 · NCT06597006 (registry estimate)
Reported efficacy
Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52) (met)
Result source: NCT04659863
Results for Homozygous Familial Hypercholesterolemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Alirocumab: 16 of 16 rows · Inclisiran: 15 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alirocumab Rows use multiple source trials | Inclisiran Rows use multiple source trials |
|---|---|---|
| Apo A1 percent change · % of baseline | 5% (n=45) vs 1.4% (n=24) placebo @ 12wk150 mg SC Q2Wa,b,c,d,e NCT03156621 · Phase 3 show 1 more dose5% (n=45) vs 1.4% (n=24) placebo @ 12wk150 mg SC Q2W NCT03156621 · Phase 3 | -1% (n=37) vs 1.6% (n=19) placebo @ 25.71wkb,c,d,e NCT03851705 · Phase 3 |
| Apo A1 percent change · % of baseline No placebo or comparator arm | 11.3% (n=18) @ 48wkc,d,f NCT03510715 · Phase 3 · registry result, not featured evidence | 5.5% (n=34) @ 102.86wkc,d,f NCT03851705 · Phase 3 |
| Apo B percent change · % of baseline | -22.5% (n=45) vs 7.2% (n=24) placebo @ 12wk150 mg SC Q2Wa,c,d,g NCT03156621 · Phase 3 show 1 more dose-22.5% (n=45) vs 7.2% (n=24) placebo @ 12wk150 mg SC Q2W NCT03156621 · Phase 3 | -14.8% (n=9) vs 10.6% (n=4) placebo @ 51.43wkc,d,g NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 |
| Apo B percent change · % of baseline No placebo or comparator arm | 0.9% (n=18) @ 48wkc,d,f NCT03510715 · Phase 3 · registry result, not featured evidence | -8% (n=34) @ 102.86wkc,d,f NCT03851705 · Phase 3 1 other source trial-7.3% (n=13) @ 102.86wk NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 |
| HDL-C percent change · % of baseline | 6.3% (n=45) vs 2.7% (n=24) placebo @ 12wk150 mg SC Q2Wa,b,c,d,e NCT03156621 · Phase 3 show 1 more dose6.3% (n=45) vs 2.7% (n=24) placebo @ 12wk150 mg SC Q2W NCT03156621 · Phase 3 | 1.5% (n=37) vs -1.9% (n=19) placebo @ 25.71wkb,c,d,e NCT03851705 · Phase 3 |
| HDL-C percent change · % of baseline No placebo or comparator arm | 10.1% (n=18) @ 48wkc,d,f NCT03510715 · Phase 3 · registry result, not featured evidence | 4.1% (n=34) @ 102.86wkc,d,f NCT03851705 · Phase 3 |
| Lp(a percent change · % of baseline | -19.6% (n=45) vs 8.8% (n=24) placebo @ 12wk150 mg SC Q2Wc,d,g NCT03156621 · Phase 3 | -1.7% (n=9) vs -12.1% (n=4) placebo @ 51.43wkc,d,g NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 |
| Lp(a percent change · % of baseline No placebo or comparator arm | -6.4% (n=18) @ 48wkc,d,f NCT03510715 · Phase 3 · registry result, not featured evidence | -8.8% (n=13) @ 102.86wkc,d,f NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 |
| Non-HDL-C percent change · % of baseline | -24.8% (n=45) vs 8% (n=24) placebo @ 12wk150 mg SC Q2Wa,c,d,g NCT03156621 · Phase 3 show 1 more dose-24.8% (n=45) vs 8% (n=24) placebo @ 12wk150 mg SC Q2W NCT03156621 · Phase 3 | -20.1% (n=9) vs 7.1% (n=4) placebo @ 51.43wkc,d,g NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 |
| Non-HDL-C percent change · % of baseline No placebo or comparator arm | 5.7% (n=18) @ 48wkc,d,f NCT03510715 · Phase 3 · registry result, not featured evidence | -5% (n=34) @ 102.86wkc,d,f NCT03851705 · Phase 3 1 other source trial-13% (n=13) @ 102.86wk NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 |
| Total Cholesterol percent change · % of baseline | -19.8% (n=45) vs 6.6% (n=24) placebo @ 12wk150 mg SC Q2Wa,b,c,d,e NCT03156621 · Phase 3 show 1 more dose-19.8% (n=45) vs 6.6% (n=24) placebo @ 12wk150 mg SC Q2W NCT03156621 · Phase 3 | -4.9% (n=37) vs -1.4% (n=19) placebo @ 25.71wkb,c,d,e NCT03851705 · Phase 3 |
| Total Cholesterol percent change · % of baseline No placebo or comparator arm | 5.5% (n=18) @ 48wkc,d,f NCT03510715 · Phase 3 · registry result, not featured evidence | -2.9% (n=34) @ 102.86wkc,d,f NCT03851705 · Phase 3 |
| Dropout rate | 0%150 mg SC Q2Wh NCT03156621 · Phase 3 show 4 more results—150 Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence | 8.1%Part 1 - Inclisirani NCT03851705 · Phase 3 show 7 more results—Part 1: Inclisiran NCT03851705 · Phase 3 —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 —Part 2: Inclisiran NCT03851705 · Phase 3 —Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 0%Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 55.6% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy |
| Discontinued due to AEs | —150 mg SC Q2Wh NCT03156621 · Phase 3 show 4 more results—150 Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence | —Part 1 - Inclisirani NCT03851705 · Phase 3 show 7 more results—Part 1: Inclisiran NCT03851705 · Phase 3 —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 —Part 2: Inclisiran NCT03851705 · Phase 3 —Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 — NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy |
| Serious AEs | —150 mg SC Q2Wh NCT03156621 · Phase 3 show 4 more results0%150 Q2W NCT03156621 · Phase 3 2.2%150 Q2W NCT03156621 · Phase 3 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence | —Part 1 - Inclisirani NCT03851705 · Phase 3 show 7 more results5.4%Part 1: Inclisiran NCT03851705 · Phase 3 —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 20.8%Part 2: Inclisiran NCT03851705 · Phase 3 0%Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 0%Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 25% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy |
| Most frequent reported AEs | 150 Q2Wh diarrhoea 6.7% (placebo 0%) headache 4.4% (placebo 8.3%) nasopharyngitis 4.4% (placebo 0%) NCT03156621 · Phase 3 show 3 more results150 Q2W nasopharyngitis 6.7% (placebo 0%) diarrhoea 2.2% (placebo 0%) headache 2.2% (placebo 8.3%) NCT03156621 · Phase 3 150 mg Q2W nasopharyngitis 22.2% alanine aminotransferase increased 11.1% aortic valve incompetence 11.1% NCT03510715 · Phase 3 · registry result, not featured evidence 75 mg Q2W/up to 150 mg Q2W aortic valve incompetence 22.2% headache 22.2% influenza 22.2% NCT03510715 · Phase 3 · registry result, not featured evidence | i diarrhoea 5.4% (placebo 0%) pyrexia 5.4% (placebo 0%) respiratory tract infection viral 5.4% (placebo 10.5%) NCT03851705 · Phase 3 show 4 more resultscorona virus infection 7.5% (placebo 0%) international normalised ratio increased 5.7% (placebo 0%) activated partial thromboplastin time prolonged 3.8% (placebo 0%) NCT03851705 · Phase 3 covid-19 44.4% (placebo 25%) abdominal pain upper 22.2% (placebo 0%) injection site reaction 22.2% (placebo 0%) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 headache 15.4% (placebo 0%) influenza 15.4% (placebo 0%) abdominal pain upper 7.7% (placebo 0%) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 abdominal pain upper 25% acne 25% angina unstable 25% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bOne study enrolled healthy volunteers and the other enrolled patients.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 12 weeks versus 25.71 weeks.
- fAssessment timepoints differ: 48 weeks versus 102.86 weeks.
- gAssessment timepoints differ: 12 weeks versus 51.43 weeks.
- hPopulation comparability has not been reviewed for these studies.
- iPopulation comparability has not been reviewed for 5 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alirocumab
show 1 more result
show 2 more results
show 2 more results
Inclisiran
show 2 more results
show 8 more results
show 2 more results
show 8 more results
show 2 more results
show 8 more results
show 2 more results
show 7 more results
show 2 more results
show 7 more results
show 1 more result
show 1 more result
+ 1 further endpoint in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alirocumab's landscape · Inclisiran's landscape